...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism
【24h】

Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism

机译:阿托伐他汀通过减轻肾脏相关代谢障碍对STZ糖尿病大鼠的肾脏保护作用

获取原文
获取原文并翻译 | 示例
           

摘要

Atorvastatin (AT) has been alternatively used for managing diabetic complications in clinic However, AT-related therapeutic potentiality remains relatively unexplored, especially in diabetic nephropathy. This study aimed to investigate the underlying potentiality that AT exerted on anti-diabetic nephropathy role against streptozotocin (STZ)-induced kidney injury in rats. STZ-diabetic rats were intragastrically administered with AT (10, 20 mg/kg/d) for consecutive 8 weeks. The effects of AT on body weight, levels of blood glucose, lipometabolism, redox state, cellular metabolism, regulator factor and kidney morphological changes were monitored by routine measurement, biochemistry assay, PT-PCR analysis, ultrastructural and pathological observations, respectively. Compared with the diabetic nephropathy rats, AT elevated the body weight of diabetic nephropathy rats (P < 0.01), effectively reduced the blood glucose level (P < 0.01), increased the levels of insulin and high-density lipoprotein cholesterol (HDL-C) in plasma (P < 0.01), and decreased the 24 h urine protein content and serum concentrations of low-density lipoprotein cholesterol (LDL-C) (P < 0.01). Meanwhile, increase in kidney tissue, the intrarenal activities of superoxide dismutase (SOD) and glutathione peroxiclase (GSH-Px) were enhanced, while the malonaldehyde (MDA) content was reduced (P < 0.01). In addition, the expression of transforming growth factor beta 1 (TGF-beta 1) mRNA in kidney tissue was notably down regulated (P < 0.01). Furthermore, AT contributed to alleviating STZ-induced nephritic damages in rats. These results demonstrate that atorvastatin exerts the effective protective role against kidney injuries of STZ-induced diabetic nephropathy rat, which the underlying mechanisms are associated with ameliorating glyco, lipometabolism, enhancing antioxidant ability, and mitigating renal damage. (C) 2014 Elsevier B.V. All rights reserved.
机译:在临床上,阿托伐他汀(AT)已被替代地用于治疗糖尿病并发症。但是,与AT相关的治疗潜力仍未得到开发,尤其是在糖尿病性肾病中。这项研究旨在调查AT发挥潜在的抗糖尿病肾病作用,对链脲佐菌素(STZ)诱导的大鼠肾脏损伤的潜在作用。对STZ糖尿病大鼠连续8周进行胃内AT(10、20 mg / kg / d)给药。通过常规测量,生化测定,PT-PCR分析,超微结构和病理观察,分别监测AT对体重,血糖水平,脂肪代谢,氧化还原状态,细胞代谢,调节因子和肾脏形态变化的影响。与糖尿病肾病大鼠相比,AT升高了糖尿病肾病大鼠的体重(P <0.01),有效降低了血糖水平(P <0.01),增加了胰岛素和高密度脂蛋白胆固醇(HDL-C)的水平在血浆中的浓度(P <0.01),并降低了24小时尿蛋白含量和低密度脂蛋白胆固醇(LDL-C)的血清浓度(P <0.01)。同时,肾脏组织增加,超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)的肾内活性增强,丙二醛(MDA)含量降低(P <0.01)。此外,肾脏组织中转化生长因子β1(TGF-β1)mRNA的表达显着下调(P <0.01)。此外,AT有助于减轻STZ诱导的大鼠肾病损害。这些结果表明阿托伐他汀对STZ诱导的糖尿病性肾病大鼠具有有效的肾脏保护作用,其潜在机制与改善糖,脂肪代谢,增强抗氧化能力和减轻肾脏损害有关。 (C)2014 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号